Clinical Trial Overview

The Phase 2 trial, initiated on December 14, 2025, enrolls patients who develop acute kidney injury (AKI) within 48 hours after cardiac surgery. The study compares autologous modified leukocyte cells with placebo. Recruitment is ongoing, and the sponsor is M2RLAB SL. The primary objectives are to assess whether the cell therapy shortens the time to renal function recovery and to evaluate safety.

Current Treatment Landscape and Unmet Need

AKI after cardiac surgery is a serious complication that markedly increases mortality and length of hospital stay. Standard care is limited to fluid management and pharmacotherapy. Recovery is slow, and the risk of permanent renal damage is high, creating a strong demand for effective therapies. A novel therapeutic approach therefore has substantial potential to improve patient outcomes.

Cell Therapy Mechanism

The modified leukocyte cells are derived from the patient’s own white blood cells and are genetically or chemically engineered to suppress inflammation and promote tissue regeneration. Preclinical data indicate that these cells act directly on injured renal tissue, reducing inflammation and accelerating repair. Using autologous cells also minimizes the risk of immune rejection.

Market and Investment Implications

If the Phase 2 trial yields positive results, it could establish a new paradigm for the acute kidney injury treatment market. The global AKI therapeutics market is currently valued at several billion dollars, and cell‑based solutions are poised to become high‑value products. This would enhance the investment appeal of early‑stage biotechs and generate significant pipeline value as the program advances into Phase 1 and Phase 3.